We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Teva (TEVA) Q3 Earnings Top but Revenues Lag Estimates
Read MoreHide Full Article
Israel-based Teva Pharmaceutical Industries Limited (TEVA - Free Report) is a global pharmaceutical company with a strong presence in the generics as well as branded markets. Teva’s main branded products include Copaxone (multiple sclerosis) and Azilect (Parkinson’s disease). Besides this, Teva’s branded product portfolio consists of respiratory products like ProAir, a short-acting beta-agonist for the treatment of bronchial spasms and exercise-induced bronchospasm, and Qvar, an inhaled corticosteroid for long-term control of chronic bronchial asthma.
Moreover, the company has several candidates in its pipeline. Earlier this week, Teva completed its acquisition of Allergan’s generics business (Actavis Generics). The company also acquired Allergan’s Anda Inc., the 4th largest distributor of generic pharmaceuticals in the U.S., for $500 million in Oct 2016.
Teva’s earnings track record has been good with the company delivering positive earnings surprises in each of the last four quarters with an average surprise of 3.75%.
Currently, TEVA has a Zacks Rank #3 (Hold), but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:
Earnings: TEVA’s third quarter earnings came in at $1.28 per share, beating consensus estimates of $1.27.
Revenues: Teva posted revenues of $5.6 billion, missing consensus estimates of $6 billion.
Key Stats: Currency fluctuations cut third quarter revenues by about $188 million. Lead branded product, Copaxone, posted worldwide sales of $1.1 billion, down 2%.
2016 Outlook: Teva has lowered its guidance for 2016. The company now expects revenues in the range of $21.6-$21.9 billion (previous guidance: $22.0-22.5 billion) and earnings in the range of $5.10-$5.20 (previously: $5.20-5.40) per share. The Zacks Consensus Estimate for 2016 revenue and earnings are $22.31 billion and $5.17 per share and, respectively.
Check back later for our full write up on this TEVA earnings report later!
Zacks’ Best Private Investment Ideas
While we are happy to share many articles like this on the website, our best recommendations and most in-depth research are not available to the public.
Starting today, for the next month, you can follow all Zacks' private buys and sells in real time. Our experts cover all kinds of trades… from value to momentum . . . from stocks under $10 to ETF and option moves . . . from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises. You can even look inside exclusive portfolios that are normally closed to new investors. Click here for Zacks' private trades >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Teva (TEVA) Q3 Earnings Top but Revenues Lag Estimates
Israel-based Teva Pharmaceutical Industries Limited (TEVA - Free Report) is a global pharmaceutical company with a strong presence in the generics as well as branded markets. Teva’s main branded products include Copaxone (multiple sclerosis) and Azilect (Parkinson’s disease). Besides this, Teva’s branded product portfolio consists of respiratory products like ProAir, a short-acting beta-agonist for the treatment of bronchial spasms and exercise-induced bronchospasm, and Qvar, an inhaled corticosteroid for long-term control of chronic bronchial asthma.
Moreover, the company has several candidates in its pipeline. Earlier this week, Teva completed its acquisition of Allergan’s generics business (Actavis Generics). The company also acquired Allergan’s Anda Inc., the 4th largest distributor of generic pharmaceuticals in the U.S., for $500 million in Oct 2016.
Teva’s earnings track record has been good with the company delivering positive earnings surprises in each of the last four quarters with an average surprise of 3.75%.
TEVA PHARM ADR Price and EPS Surprise
TEVA PHARM ADR Price and EPS Surprise | TEVA PHARM ADR Quote
Currently, TEVA has a Zacks Rank #3 (Hold), but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:
Earnings: TEVA’s third quarter earnings came in at $1.28 per share, beating consensus estimates of $1.27.
Revenues: Teva posted revenues of $5.6 billion, missing consensus estimates of $6 billion.
Key Stats: Currency fluctuations cut third quarter revenues by about $188 million. Lead branded product, Copaxone, posted worldwide sales of $1.1 billion, down 2%.
2016 Outlook: Teva has lowered its guidance for 2016. The company now expects revenues in the range of $21.6-$21.9 billion (previous guidance: $22.0-22.5 billion) and earnings in the range of $5.10-$5.20 (previously: $5.20-5.40) per share. The Zacks Consensus Estimate for 2016 revenue and earnings are $22.31 billion and $5.17 per share and, respectively.
Check back later for our full write up on this TEVA earnings report later!
Zacks’ Best Private Investment Ideas
While we are happy to share many articles like this on the website, our best recommendations and most in-depth research are not available to the public.
Starting today, for the next month, you can follow all Zacks' private buys and sells in real time. Our experts cover all kinds of trades… from value to momentum . . . from stocks under $10 to ETF and option moves . . . from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises. You can even look inside exclusive portfolios that are normally closed to new investors. Click here for Zacks' private trades >>